Glycemia Determines the Effect of Type 2 Diabetes Risk Genes on Insulin Secretion

Overview

Journal Diabetes

Specialty Endocrinology

Date 2010 Aug 31

PMID 20802253

Citations 24

Authors

Martin Heni

Caroline Ketterer

Claus Thamer

Silke A Herzberg-Schafer

Martina Guthoff

Norbert Stefan

Fausto Machicao

Harald Staiger

Andreas Fritsche

Hans-Ulrich Haring

Affiliations

Soon will be listed here.

Abstract

Objective: Several single nucleotide polymorphisms (SNPs) in diabetes risk genes reduce glucose- and/or incretin-induced insulin secretion. Here, we investigated interactions between glycemia and such diabetes risk polymorphisms.

Research Design And Methods: Insulin secretion was assessed by insulinogenic index and areas under the curve of C-peptide/glucose in 1,576 subjects using an oral glucose tolerance test (OGTT). Participants were genotyped for 10 diabetes risk SNPs associated with β-cell dysfunction: rs5215 (KCNJ11), rs13266634 (SLC30A8), rs7754840 (CDKAL1), rs10811661 (CDKN2A/2B), rs10830963 (MTNR1B), rs7903146 (TCF7L2), rs10010131 (WFS1), rs7923837 (HHEX), rs151290 (KCNQ1), and rs4402960 (IGF2BP2). Furthermore, the impact of the interaction between genetic variation in TCF7L2 and glycemia on changes in insulin secretion was tested in 315 individuals taking part in a lifestyle intervention study.

Results: For the SNPs in TCF7L2 and WFS1, we found a significant interaction between glucose control and insulin secretion (all P ≤ 0.0018 for glucose × genotype). When plotting insulin secretion against glucose at 120 min OGTT, the compromising SNP effects on insulin secretion are most apparent under high glucose. In the longitudinal study, rs7903146 in TCF7L2 showed a significant interaction with baseline glucose tolerance upon change in insulin secretion (P = 0.0027). Increased glucose levels at baseline predicted an increase in insulin secretion upon improvement of glycemia by lifestyle intervention only in carriers of the risk alleles.

Conclusions: For the diabetes risk genes TCF7L2 and WFS1, which are associated with impaired incretin signaling, the level of glycemia determines SNP effects on insulin secretion. This indicates the increasing relevance of these SNPs during the progression of prediabetes stages toward clinically overt type 2 diabetes.

Citing Articles

Comprehensive overview of disease models for Wolfram syndrome: toward effective treatments.

Morikawa S, Tanabe K, Kaneko N, Hishimura N, Nakamura A Mamm Genome. 2024; 35(1):1-12.

PMID: 38351344 DOI: 10.1007/s00335-023-10028-x.

Relationship Between Hypertriglyceridemic Waist Phenotype and Disposition Index in Chinese Men With Normal Glucose Tolerance.

Liu X, Ma C, Wang R, Lu N, Ma C, Yin F Am J Mens Health. 2023; 17(3):15579883231170172.

PMID: 37131294 PMC: 10159256. DOI: 10.1177/15579883231170172.

No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect.

Mathiesen D, Bagger J, Hansen K, Junker A, Plamboeck A, Harring S Endocr Connect. 2020; 9(12):1221-1232.

PMID: 33252353 PMC: 7774769. DOI: 10.1530/EC-20-0471.

GLP-1 Receptor Agonists and Diabetic Kidney Disease: A Call of Attention to Nephrologists.

Gorriz J, Soler M, Navarro-Gonzalez J, Garcia-Carro C, Puchades M, DMarco L J Clin Med. 2020; 9(4).

PMID: 32235471 PMC: 7231090. DOI: 10.3390/jcm9040947.

Glucagon-like peptide 1 (GLP-1).

Muller T, Finan B, Bloom S, DAlessio D, Drucker D, Flatt P Mol Metab. 2019; 30:72-130.

PMID: 31767182 PMC: 6812410. DOI: 10.1016/j.molmet.2019.09.010.

References

Poitout V, Robertson R . Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev. 2007; 29(3):351-66. PMC: 2528858. DOI: 10.1210/er.2007-0023. View

Florez J, Jablonski K, Bayley N, Pollin T, de Bakker P, Shuldiner A . TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006; 355(3):241-50. PMC: 1762036. DOI: 10.1056/NEJMoa062418. View

Staiger H, Machicao F, Schafer S, Kirchhoff K, Kantartzis K, Guthoff M . Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine beta-cell function. PLoS One. 2008; 3(12):e3962. PMC: 2597741. DOI: 10.1371/journal.pone.0003962. View

Kirchhoff K, Machicao F, Haupt A, Schafer S, Tschritter O, Staiger H . Polymorphisms in the TCF7L2, CDKAL1 and SLC30A8 genes are associated with impaired proinsulin conversion. Diabetologia. 2008; 51(4):597-601. DOI: 10.1007/s00125-008-0926-y. View

McCarthy M, Zeggini E . Genome-wide association studies in type 2 diabetes. Curr Diab Rep. 2009; 9(2):164-71. PMC: 2694564. DOI: 10.1007/s11892-009-0027-4. View

Tschritter O, Stumvoll M, Machicao F, Holzwarth M, Weisser M, Maerker E . The prevalent Glu23Lys polymorphism in the potassium inward rectifier 6.2 (KIR6.2) gene is associated with impaired glucagon suppression in response to hyperglycemia. Diabetes. 2002; 51(9):2854-60. DOI: 10.2337/diabetes.51.9.2854. View

Weyrich P, Stefan N, Haring H, Laakso M, Fritsche A . Effect of genotype on success of lifestyle intervention in subjects at risk for type 2 diabetes. J Mol Med (Berl). 2006; 85(2):107-17. DOI: 10.1007/s00109-006-0134-5. View

Grarup N, Andersen G . Gene-environment interactions in the pathogenesis of type 2 diabetes and metabolism. Curr Opin Clin Nutr Metab Care. 2007; 10(4):420-6. DOI: 10.1097/MCO.0b013e3281e2c9ab. View

Staiger H, Machicao F, Stefan N, Tschritter O, Thamer C, Kantartzis K . Polymorphisms within novel risk loci for type 2 diabetes determine beta-cell function. PLoS One. 2007; 2(9):e832. PMC: 1952072. DOI: 10.1371/journal.pone.0000832. View

10.

Schafer S, Kantartzis K, Machann J, Venter C, Niess A, Schick F . Lifestyle intervention in individuals with normal versus impaired glucose tolerance. Eur J Clin Invest. 2007; 37(7):535-43. DOI: 10.1111/j.1365-2362.2007.01820.x. View

11.

Stumvoll M, Goldstein B, van Haeften T . Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005; 365(9467):1333-46. DOI: 10.1016/S0140-6736(05)61032-X. View

12.

Schafer S, Mussig K, Staiger H, Machicao F, Stefan N, Gallwitz B . A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion. Diabetologia. 2009; 52(6):1075-82. DOI: 10.1007/s00125-009-1344-5. View

13.

Mussig K, Staiger H, Machicao F, Kirchhoff K, Guthoff M, Schafer S . Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion. Diabetes. 2009; 58(7):1715-20. PMC: 2699873. DOI: 10.2337/db08-1589. View

14.

Drucker D . The biology of incretin hormones. Cell Metab. 2006; 3(3):153-65. DOI: 10.1016/j.cmet.2006.01.004. View

15.

Staiger H, Machicao F, Fritsche A, Haring H . Pathomechanisms of type 2 diabetes genes. Endocr Rev. 2009; 30(6):557-85. DOI: 10.1210/er.2009-0017. View

16.

Schafer S, Tschritter O, Machicao F, Thamer C, Stefan N, Gallwitz B . Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms. Diabetologia. 2007; 50(12):2443-50. PMC: 2063563. DOI: 10.1007/s00125-007-0753-6. View

17.

Andreasen C, Andersen G . Gene-environment interactions and obesity--further aspects of genomewide association studies. Nutrition. 2009; 25(10):998-1003. DOI: 10.1016/j.nut.2009.06.001. View

18.

Kjems L, Holst J, Volund A, Madsbad S . The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes. 2003; 52(2):380-6. DOI: 10.2337/diabetes.52.2.380. View

19.

Wareham N, Franks P, Harding A . Establishing the role of gene-environment interactions in the etiology of type 2 diabetes. Endocrinol Metab Clin North Am. 2002; 31(3):553-66. DOI: 10.1016/s0889-8529(02)00007-5. View

20.

Tuomilehto J, Lindstrom J, Eriksson J, Valle T, Hamalainen H, Ilanne-Parikka P . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001; 344(18):1343-50. DOI: 10.1056/NEJM200105033441801. View